Chronic fluoxetine upregulates activity, protein and mRNA levels of cytosolic phospholipase A2 in rat frontal cortex
Chronic lithium and carbamazepine, which are effective against mania in bipolar disorder, decrease the activity of cytosolic phospholipase A 2 (cPLA 2 ) and the turnover rate of arachidonic acid in phospholipids in rat brain. Assuming that stages of bipolar disorder are related to brain arachidonic...
Gespeichert in:
| Veröffentlicht in: | The pharmacogenomics journal 2006-11, Vol.6 (6), p.413-420 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 420 |
|---|---|
| container_issue | 6 |
| container_start_page | 413 |
| container_title | The pharmacogenomics journal |
| container_volume | 6 |
| creator | Rao, J S Ertley, R N Lee, H-J Rapoport, S I Bazinet, R P |
| description | Chronic lithium and carbamazepine, which are effective against mania in bipolar disorder, decrease the activity of cytosolic phospholipase A
2
(cPLA
2
) and the turnover rate of arachidonic acid in phospholipids in rat brain. Assuming that stages of bipolar disorder are related to brain arachidonic acid metabolism, we hypothesized that drugs effective in depression would increase cPLA
2
activity. To test this hypothesis, adult male CDF-344 rats were administered fluoxetine (10 mg/kg intraperitoneally (i.p.) or saline (control) (i.p.) chronically for 21 days. Frontal cortex cPLA
2
protein, phosphorylated cPLA
2
, activity and mRNA levels were increased after chronic fluoxetine. Transcription factors (activator protein-1, activator protein-2, glucocorticoid response element, polyoma enhancer element-3 and nuclear factor-kappa B) that are known to regulate cPLA
2
gene expression were not significantly changed by chronic fluoxetine, but nuclear AU-rich element/poly(U)-binding/degradation factor-1 RNA-stabilizing protein was increased significantly. The results suggest that chronic fluoxetine increases brain cPLA
2
gene expression post-transcriptionally by increasing cPLA
2
mRNA stabilization. Chronic fluoxetine's effect on cPLA
2
expression was opposite to the effect reported with chronic lithium or carbamazepine administration, and may be part of fluoxetine's mode of action. |
| doi_str_mv | 10.1038/sj.tpj.6500391 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_68172627</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A189267148</galeid><sourcerecordid>A189267148</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4101-3e8cf12209d9f6328988229b32617d140e5bdc6feecea300be9dc65883e517c93</originalsourceid><addsrcrecordid>eNp1kl1rFDEUhgdRbK3eeilBoVfONh8zmeRyWawKRUEUvAvZzMk2Q2YyJpnS_fdN7cJCaQkhX895zznkrar3BK8IZuIiDas8DyveYswkeVGdkqZjNSEtfvl_j2vK5d-T6k1KA8aEk068rk4I54xz0ZxWeXMdw-QMsn4Jt5DdBGiZI-wWrzMkpE12Ny7vP6M5hgxuQnrq0fjrxxp5uAGfULDI7HNIwReV-TqkMr2bdQK0pqgERJ2RLUmy9siEmOH2bfXKap_g3WE9q_5cfvm9-VZf_fz6fbO-qk1DMKkZCGMJpVj20nJGhRSCUrlltLTRkwZDu-0NtwAGNMN4C7IcWyEYtKQzkp1V5w-6pfZ_C6SsRpcMeK8nCEtSXJCOctoV8NMjcAhLnEptivKGdBh3sinUx2cp2kkuKaVHqZ32oNxkQ47a3OdVayIk5R1pRKFWT1Bl9DA6Eyawrtw_FWBiSCmCVXN0o457RbC6d4JKgypOUAcnlIAPh2KX7Qj9ET98fQEuHoBUnqYdxGM3z0jeAUCUvhI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>227969222</pqid></control><display><type>article</type><title>Chronic fluoxetine upregulates activity, protein and mRNA levels of cytosolic phospholipase A2 in rat frontal cortex</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Rao, J S ; Ertley, R N ; Lee, H-J ; Rapoport, S I ; Bazinet, R P</creator><creatorcontrib>Rao, J S ; Ertley, R N ; Lee, H-J ; Rapoport, S I ; Bazinet, R P</creatorcontrib><description>Chronic lithium and carbamazepine, which are effective against mania in bipolar disorder, decrease the activity of cytosolic phospholipase A
2
(cPLA
2
) and the turnover rate of arachidonic acid in phospholipids in rat brain. Assuming that stages of bipolar disorder are related to brain arachidonic acid metabolism, we hypothesized that drugs effective in depression would increase cPLA
2
activity. To test this hypothesis, adult male CDF-344 rats were administered fluoxetine (10 mg/kg intraperitoneally (i.p.) or saline (control) (i.p.) chronically for 21 days. Frontal cortex cPLA
2
protein, phosphorylated cPLA
2
, activity and mRNA levels were increased after chronic fluoxetine. Transcription factors (activator protein-1, activator protein-2, glucocorticoid response element, polyoma enhancer element-3 and nuclear factor-kappa B) that are known to regulate cPLA
2
gene expression were not significantly changed by chronic fluoxetine, but nuclear AU-rich element/poly(U)-binding/degradation factor-1 RNA-stabilizing protein was increased significantly. The results suggest that chronic fluoxetine increases brain cPLA
2
gene expression post-transcriptionally by increasing cPLA
2
mRNA stabilization. Chronic fluoxetine's effect on cPLA
2
expression was opposite to the effect reported with chronic lithium or carbamazepine administration, and may be part of fluoxetine's mode of action.</description><identifier>ISSN: 1470-269X</identifier><identifier>EISSN: 1473-1150</identifier><identifier>DOI: 10.1038/sj.tpj.6500391</identifier><identifier>PMID: 16636684</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Activator protein 1 ; Adaptor Protein Complex 2 - metabolism ; Affective disorders ; Animals ; Arachidonic acid ; Biomedicine ; Bipolar disorder ; Carbamazepine ; Cortex (frontal) ; Cytosol - enzymology ; Drug metabolism ; Fluoxetine ; Fluoxetine - pharmacology ; Frontal Lobe - drug effects ; Frontal Lobe - enzymology ; Gene Expression ; Gene Expression - drug effects ; Glucocorticoids ; Heterogeneous Nuclear Ribonucleoprotein D0 ; Heterogeneous-Nuclear Ribonucleoprotein D - metabolism ; Human Genetics ; Lithium ; Male ; NF-κB protein ; Oncology ; original-article ; Pharmacotherapy ; Phospholipase A2 ; Phospholipases A - biosynthesis ; Phospholipases A - genetics ; Phospholipases A2 ; Phospholipids ; Phosphorylation ; Post-transcription ; Proteins ; Psychopharmacology ; Rats ; RNA, Messenger - metabolism ; Transcription Factor AP-1 - metabolism ; Transcription factors ; Transcription Factors - metabolism ; Up-Regulation</subject><ispartof>The pharmacogenomics journal, 2006-11, Vol.6 (6), p.413-420</ispartof><rights>Springer Nature Limited 2006</rights><rights>COPYRIGHT 2006 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Nov 2006</rights><rights>Nature Publishing Group 2006.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4101-3e8cf12209d9f6328988229b32617d140e5bdc6feecea300be9dc65883e517c93</citedby><cites>FETCH-LOGICAL-c4101-3e8cf12209d9f6328988229b32617d140e5bdc6feecea300be9dc65883e517c93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16636684$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rao, J S</creatorcontrib><creatorcontrib>Ertley, R N</creatorcontrib><creatorcontrib>Lee, H-J</creatorcontrib><creatorcontrib>Rapoport, S I</creatorcontrib><creatorcontrib>Bazinet, R P</creatorcontrib><title>Chronic fluoxetine upregulates activity, protein and mRNA levels of cytosolic phospholipase A2 in rat frontal cortex</title><title>The pharmacogenomics journal</title><addtitle>Pharmacogenomics J</addtitle><addtitle>Pharmacogenomics J</addtitle><description>Chronic lithium and carbamazepine, which are effective against mania in bipolar disorder, decrease the activity of cytosolic phospholipase A
2
(cPLA
2
) and the turnover rate of arachidonic acid in phospholipids in rat brain. Assuming that stages of bipolar disorder are related to brain arachidonic acid metabolism, we hypothesized that drugs effective in depression would increase cPLA
2
activity. To test this hypothesis, adult male CDF-344 rats were administered fluoxetine (10 mg/kg intraperitoneally (i.p.) or saline (control) (i.p.) chronically for 21 days. Frontal cortex cPLA
2
protein, phosphorylated cPLA
2
, activity and mRNA levels were increased after chronic fluoxetine. Transcription factors (activator protein-1, activator protein-2, glucocorticoid response element, polyoma enhancer element-3 and nuclear factor-kappa B) that are known to regulate cPLA
2
gene expression were not significantly changed by chronic fluoxetine, but nuclear AU-rich element/poly(U)-binding/degradation factor-1 RNA-stabilizing protein was increased significantly. The results suggest that chronic fluoxetine increases brain cPLA
2
gene expression post-transcriptionally by increasing cPLA
2
mRNA stabilization. Chronic fluoxetine's effect on cPLA
2
expression was opposite to the effect reported with chronic lithium or carbamazepine administration, and may be part of fluoxetine's mode of action.</description><subject>Activator protein 1</subject><subject>Adaptor Protein Complex 2 - metabolism</subject><subject>Affective disorders</subject><subject>Animals</subject><subject>Arachidonic acid</subject><subject>Biomedicine</subject><subject>Bipolar disorder</subject><subject>Carbamazepine</subject><subject>Cortex (frontal)</subject><subject>Cytosol - enzymology</subject><subject>Drug metabolism</subject><subject>Fluoxetine</subject><subject>Fluoxetine - pharmacology</subject><subject>Frontal Lobe - drug effects</subject><subject>Frontal Lobe - enzymology</subject><subject>Gene Expression</subject><subject>Gene Expression - drug effects</subject><subject>Glucocorticoids</subject><subject>Heterogeneous Nuclear Ribonucleoprotein D0</subject><subject>Heterogeneous-Nuclear Ribonucleoprotein D - metabolism</subject><subject>Human Genetics</subject><subject>Lithium</subject><subject>Male</subject><subject>NF-κB protein</subject><subject>Oncology</subject><subject>original-article</subject><subject>Pharmacotherapy</subject><subject>Phospholipase A2</subject><subject>Phospholipases A - biosynthesis</subject><subject>Phospholipases A - genetics</subject><subject>Phospholipases A2</subject><subject>Phospholipids</subject><subject>Phosphorylation</subject><subject>Post-transcription</subject><subject>Proteins</subject><subject>Psychopharmacology</subject><subject>Rats</subject><subject>RNA, Messenger - metabolism</subject><subject>Transcription Factor AP-1 - metabolism</subject><subject>Transcription factors</subject><subject>Transcription Factors - metabolism</subject><subject>Up-Regulation</subject><issn>1470-269X</issn><issn>1473-1150</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kl1rFDEUhgdRbK3eeilBoVfONh8zmeRyWawKRUEUvAvZzMk2Q2YyJpnS_fdN7cJCaQkhX895zznkrar3BK8IZuIiDas8DyveYswkeVGdkqZjNSEtfvl_j2vK5d-T6k1KA8aEk068rk4I54xz0ZxWeXMdw-QMsn4Jt5DdBGiZI-wWrzMkpE12Ny7vP6M5hgxuQnrq0fjrxxp5uAGfULDI7HNIwReV-TqkMr2bdQK0pqgERJ2RLUmy9siEmOH2bfXKap_g3WE9q_5cfvm9-VZf_fz6fbO-qk1DMKkZCGMJpVj20nJGhRSCUrlltLTRkwZDu-0NtwAGNMN4C7IcWyEYtKQzkp1V5w-6pfZ_C6SsRpcMeK8nCEtSXJCOctoV8NMjcAhLnEptivKGdBh3sinUx2cp2kkuKaVHqZ32oNxkQ47a3OdVayIk5R1pRKFWT1Bl9DA6Eyawrtw_FWBiSCmCVXN0o457RbC6d4JKgypOUAcnlIAPh2KX7Qj9ET98fQEuHoBUnqYdxGM3z0jeAUCUvhI</recordid><startdate>20061101</startdate><enddate>20061101</enddate><creator>Rao, J S</creator><creator>Ertley, R N</creator><creator>Lee, H-J</creator><creator>Rapoport, S I</creator><creator>Bazinet, R P</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20061101</creationdate><title>Chronic fluoxetine upregulates activity, protein and mRNA levels of cytosolic phospholipase A2 in rat frontal cortex</title><author>Rao, J S ; Ertley, R N ; Lee, H-J ; Rapoport, S I ; Bazinet, R P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4101-3e8cf12209d9f6328988229b32617d140e5bdc6feecea300be9dc65883e517c93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Activator protein 1</topic><topic>Adaptor Protein Complex 2 - metabolism</topic><topic>Affective disorders</topic><topic>Animals</topic><topic>Arachidonic acid</topic><topic>Biomedicine</topic><topic>Bipolar disorder</topic><topic>Carbamazepine</topic><topic>Cortex (frontal)</topic><topic>Cytosol - enzymology</topic><topic>Drug metabolism</topic><topic>Fluoxetine</topic><topic>Fluoxetine - pharmacology</topic><topic>Frontal Lobe - drug effects</topic><topic>Frontal Lobe - enzymology</topic><topic>Gene Expression</topic><topic>Gene Expression - drug effects</topic><topic>Glucocorticoids</topic><topic>Heterogeneous Nuclear Ribonucleoprotein D0</topic><topic>Heterogeneous-Nuclear Ribonucleoprotein D - metabolism</topic><topic>Human Genetics</topic><topic>Lithium</topic><topic>Male</topic><topic>NF-κB protein</topic><topic>Oncology</topic><topic>original-article</topic><topic>Pharmacotherapy</topic><topic>Phospholipase A2</topic><topic>Phospholipases A - biosynthesis</topic><topic>Phospholipases A - genetics</topic><topic>Phospholipases A2</topic><topic>Phospholipids</topic><topic>Phosphorylation</topic><topic>Post-transcription</topic><topic>Proteins</topic><topic>Psychopharmacology</topic><topic>Rats</topic><topic>RNA, Messenger - metabolism</topic><topic>Transcription Factor AP-1 - metabolism</topic><topic>Transcription factors</topic><topic>Transcription Factors - metabolism</topic><topic>Up-Regulation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rao, J S</creatorcontrib><creatorcontrib>Ertley, R N</creatorcontrib><creatorcontrib>Lee, H-J</creatorcontrib><creatorcontrib>Rapoport, S I</creatorcontrib><creatorcontrib>Bazinet, R P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The pharmacogenomics journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rao, J S</au><au>Ertley, R N</au><au>Lee, H-J</au><au>Rapoport, S I</au><au>Bazinet, R P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic fluoxetine upregulates activity, protein and mRNA levels of cytosolic phospholipase A2 in rat frontal cortex</atitle><jtitle>The pharmacogenomics journal</jtitle><stitle>Pharmacogenomics J</stitle><addtitle>Pharmacogenomics J</addtitle><date>2006-11-01</date><risdate>2006</risdate><volume>6</volume><issue>6</issue><spage>413</spage><epage>420</epage><pages>413-420</pages><issn>1470-269X</issn><eissn>1473-1150</eissn><abstract>Chronic lithium and carbamazepine, which are effective against mania in bipolar disorder, decrease the activity of cytosolic phospholipase A
2
(cPLA
2
) and the turnover rate of arachidonic acid in phospholipids in rat brain. Assuming that stages of bipolar disorder are related to brain arachidonic acid metabolism, we hypothesized that drugs effective in depression would increase cPLA
2
activity. To test this hypothesis, adult male CDF-344 rats were administered fluoxetine (10 mg/kg intraperitoneally (i.p.) or saline (control) (i.p.) chronically for 21 days. Frontal cortex cPLA
2
protein, phosphorylated cPLA
2
, activity and mRNA levels were increased after chronic fluoxetine. Transcription factors (activator protein-1, activator protein-2, glucocorticoid response element, polyoma enhancer element-3 and nuclear factor-kappa B) that are known to regulate cPLA
2
gene expression were not significantly changed by chronic fluoxetine, but nuclear AU-rich element/poly(U)-binding/degradation factor-1 RNA-stabilizing protein was increased significantly. The results suggest that chronic fluoxetine increases brain cPLA
2
gene expression post-transcriptionally by increasing cPLA
2
mRNA stabilization. Chronic fluoxetine's effect on cPLA
2
expression was opposite to the effect reported with chronic lithium or carbamazepine administration, and may be part of fluoxetine's mode of action.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>16636684</pmid><doi>10.1038/sj.tpj.6500391</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-269X |
| ispartof | The pharmacogenomics journal, 2006-11, Vol.6 (6), p.413-420 |
| issn | 1470-269X 1473-1150 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68172627 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Activator protein 1 Adaptor Protein Complex 2 - metabolism Affective disorders Animals Arachidonic acid Biomedicine Bipolar disorder Carbamazepine Cortex (frontal) Cytosol - enzymology Drug metabolism Fluoxetine Fluoxetine - pharmacology Frontal Lobe - drug effects Frontal Lobe - enzymology Gene Expression Gene Expression - drug effects Glucocorticoids Heterogeneous Nuclear Ribonucleoprotein D0 Heterogeneous-Nuclear Ribonucleoprotein D - metabolism Human Genetics Lithium Male NF-κB protein Oncology original-article Pharmacotherapy Phospholipase A2 Phospholipases A - biosynthesis Phospholipases A - genetics Phospholipases A2 Phospholipids Phosphorylation Post-transcription Proteins Psychopharmacology Rats RNA, Messenger - metabolism Transcription Factor AP-1 - metabolism Transcription factors Transcription Factors - metabolism Up-Regulation |
| title | Chronic fluoxetine upregulates activity, protein and mRNA levels of cytosolic phospholipase A2 in rat frontal cortex |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T08%3A29%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20fluoxetine%20upregulates%20activity,%20protein%20and%20mRNA%20levels%20of%20cytosolic%20phospholipase%20A2%20in%20rat%20frontal%20cortex&rft.jtitle=The%20pharmacogenomics%20journal&rft.au=Rao,%20J%20S&rft.date=2006-11-01&rft.volume=6&rft.issue=6&rft.spage=413&rft.epage=420&rft.pages=413-420&rft.issn=1470-269X&rft.eissn=1473-1150&rft_id=info:doi/10.1038/sj.tpj.6500391&rft_dat=%3Cgale_proqu%3EA189267148%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=227969222&rft_id=info:pmid/16636684&rft_galeid=A189267148&rfr_iscdi=true |